TAK earnings call for the period ending March 31, 2020.
News & Analysis: Takeda Pharmaceutical Company
CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy
Six companies will work together to develop a plasma-derived antibody product to fight SARS-CoV-2.
The plasma of people who have recovered from the novel coronavirus contains antibodies that could help current patients fight the infection.
The plasma of those who have recovered contains antibodies to the novel coronavirus, which could help other patients fight it off.
Forget vaccines or antivirals -- antibodies from patients who have recovered could be the secret to beating COVID-19.
The battle to defeat the coronavirus will be won. But victory won't come as quickly as anyone would like.
Plasma-derived therapies have proven effective in the treatment of severe acute viral respiratory infections.
A huge acquisition could get this overlooked giant on investors' radar.
The integration of Shire is progressing more quickly than the company had expected.
This global pharmaceutical company has a healthy dividend and a bevy of new drugs set to enter the market in the coming years.